Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c01117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Meijiao Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China. Hauptthemen laut MEDLINE: Verteporfin, Photochemotherapy, Uveal Neoplasms, Melanoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: People's Government of Jilin Province, Jilin University, Department of Science and Technology of Jilin Province.
Abstract (Originalsprache)
Uveal melanoma (UM) is the most common primary ocular malignancy in adults and has high mortality. Recurrence, metastasis, and therapeutic resistance are frequently observed in UM, but no beneficial systemic therapy is available, presenting an urgent need for developing effective therapeutic drugs. Verteporfin (VP) is a photosensitizer and a Yes-Associated Protein (YAP) inhibitor that has been used in clinical practice. However, VP's lack of tumor targetability, poor biocompatibility, and relatively low treatment efficacy hamper its application in UM management. Herein, we developed a biocompatible CD44-targeting hyaluronic acid nanoparticle (HANP) carrying VP (HANP/VP) to improve UM treatment efficacy. We found that HANP/VP showed a stronger inhibitory effect on cell proliferation than that of free VP in UM cells. Systemic delivery of HANP/VP led to targeted accumulation in the UM-tumor-bearing mouse model. Notably, HANP/VP mediated photodynamic therapy (PDT) significantly inhibited UM tumor growth after laser irradiation compared with no treatment or free VP treatment. Consistently, in HANP/VP treated tumors after laser irradiation, the tumor proliferation and YAP expression level were decreased, while the apoptotic tumor cell and CD8+ immune cell levels were elevated, contributing to effective tumor growth inhibition. Overall, the results of this preclinical study showed that HANP/VP is an effective nanomedicine for tumor treatment through PDT and inhibition of YAP in the UM tumor mouse model. Combining phototherapy and molecular-targeted therapy offers a promising approach for aggressive UM management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China.
- Department of Surgery and Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, United States.
- Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University, Changchun 130033, Jilin Province, China.
- Department of Hematology and Medical Oncology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, United States.
ORCID-Profile: Rui Tian
Förderung
- People's Government of Jilin Province
- Jilin University
- Department of Science and Technology of Jilin Province
- National Natural Science Foundation of China
- Health Technology Innovation Project of Jilin Province
Zitieren
APA
Song, M., Zhu, L., Zhang, L., Ge, X., Cao, J., Teng, Y., & Tian, R. (2024). Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c01117
Vancouver
Song M, Zhu L, Zhang L, Ge X, Cao J, Teng Y, et al. Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c01117
BibTeX
@article{Song2024,
author = {Song, Meijiao and Zhu, Lei and Zhang, Lumeng and Ge, Xiaoguang and Cao, Jinfeng and Teng, Yong and Tian, Rui},
title = {Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c01117}
}
EUVIMED